Search

Your search keyword '"Garcia, Lourdes"' showing total 7 results
Start Over Author "Garcia, Lourdes" Journal clinical infectious diseases
7 results on '"Garcia, Lourdes"'

1. Characterization of Household and Community Shedding and Transmission of Oral Polio Vaccine in Mexican Communities With Varying Vaccination Coverage

Author

Altamirano, Jonathan, Purington, Natasha, Behl, Rasika, Sarnquist, Clea, Holubar, Marisa, García-García, Lourdes, Ferreyra-Reyes, Leticia, Montero-Campos, Rogelio, Cruz-Hervert, Luis Pablo, Boyle, Shanda, Modlin, John, van Hoorebeke, Christopher, Leary, Sean, Huang, ChunHong, Sommer, Marvin, Ferreira-Guerrero, Elizabeth, Delgado-Sanchez, Guadalupe, Canizales-Quintero, Sergio, Ortega, José Luis Díaz, Desai, Manisha, and Maldonado, Yvonne A.

Published
2018

3. Protocol Paper : Oral Poliovirus Vaccine Transmissibility in Communities After Cessation of Routine Oral Poliovirus Vaccine Immunization

Author

Sarnquist, Clea, Holubar, Marisa, García-García, Lourdes, Ferreyra-Reyes, Leticia, Delgado-Sánchez, Guadalupe, Cruz-Hervert, Luis Pablo, Montero-Campos, Rogelio, Altamirano, Jonathan, Purington, Natasha, Boyle, Shanda, Modlin, John, Ferreira-Guerrero, Elizabeth, Canizales-Quintero, Sergio, Ortega, José Luis Díaz, Desai, Manisha, and Maldonado, Yvonne A.

Published
2018

4. Seroprevalence of Poliomyelitis Antibodies Among Children Aged 1 to 4 Years Old and Factors Associated With Poliovirus Susceptibility; Mexican Health and Nutrition Survey, 2012

Author

Díaz-Quiñónez, José Alberto, Díaz-Ortega, José Luis, Cruz-Hervert, Pablo, Ferreira-Guerrero, Elizabeth, Delgado-Sánchez, Guadalupe, Ferreyra-Reyes, Leticia, López-Martínez, Irma, Torres-Longoria, Belem, Aparicio-Antonio, Rodrigo, Montero-Campos, Rogelio, Mongua-Rodríguez, Norma, and Garcia-Garcia, Lourdes

Published
2018

6. Treatment Outcomes of Patients With Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis According to Drug Susceptibility Testing to First- and Second-line Drugs: An Individual Patient Data Meta-analysis

Author

Collaborative Group for Meta-analysis of Individual Patient Data in MDR-TB, Bastos, Mayara L., Hussain, Hamidah, Weyer, Karin, Garcia-Garcia, Lourdes, Leimane, Vaira, Leung, Chi Chiu, Narita, Masahiro, Penã, Jose M., Ponce-de-Leon, Alfredo, Seung, Kwonjune J., Shean, Karen, Sifuentes-Osornio, José, Van der Walt, Martie, Van der Werf, Tjip S., Yew, Wing Wai, and Menzies, Dick

Published
2014
Full Text
View/download PDF

7. Treatment Outcomes of Patients With Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis According to Drug Susceptibility Testing to First- and Second-line Drugs

Author

Bastos, Mayara L., Hussain, Hamidah, Weyer, Karin, Garcia-Garcia, Lourdes, Leimane, Vaira, Leung, Chi Chiu, Narita, Masahiro, Penã, Jose M., Ponce-de-Leon, Alfredo, Seung, Kwonjune J., Shean, Karen, Sifuentes-Osornio, José, Van der Walt, Martie, Van der Werf, Tjip S., Yew, Wing Wai, Menzies, Dick, Ahuja, S., Ashkin, D., Avendaño, M., Banerjee, R., Bauer, M., Becerra, M., Benedetti, A., Burgos, M., Centis, R., Chan, E.D., Chiang, C.Y., Cobelens, F., Cox, H., D'Ambrosio, L., de Lange, W.C.M., DeRiemer, K., Enarson, D., Falzon, D., Flanagan, K., Flood, J., Gandhi, N., Garcia-Garcia, L., Granich, R.M., Hollm-Delgado, M.G., Holtz, T.H., Hopewell, P., Iseman, M., Jarlsberg, L.G., Keshavjee, S., Kim, H.R., Koh, W.J., Lancaster, J., Lange, C., Leimane, V., Leung, C.C., Li, J., Menzies, D., Migliori, G.B., Mitnick, C.M., Narita, M., Nathanson, E., Odendaal, R., O'Riordan, P., Pai, M., Palmero, D., Park, S.K., Pasvol, G., Pena, J., Pérez-Guzmán, C., Ponce-de-Leon, A., Quelapio, M.I.D., Quy, H.T., Riekstina, V., Robert, J., Royce, S., Salim, M., Schaaf, H.S., Seung, K.J., Shah, L., Shean, K., Shim, T.S., Shin, S.S., Shiraishi, Y., Sifuentes-Osornio, J., Sotgiu, G., Strand, M.J., Sung, S.W., Tabarsi, P., Tupasi, T.E., Vargas, M.H., van Altena, R., van der Walt, M., van der Werf, T.S., Viiklepp, P., Westenhouse, J., Yew, W.W., Yim, J.J., and Microbes in Health and Disease (MHD)

Subjects
Microbiology (medical), Drug, Adult, Male, medicine.medical_specialty, Tuberculosis, media_common.quotation_subject, Extensively Drug-Resistant Tuberculosis, PULMONARY TUBERCULOSIS, CITY, CALIFORNIA, Antitubercular Agents, drug susceptibility test, Microbial Sensitivity Tests, treatment outcomes, Pharmacology, THERAPY, Young Adult, Pharmacotherapy, Risk Factors, Internal medicine, Tuberculosis, Multidrug-Resistant, medicine, Odds Ratio, STANDARDIZED REGIMENS, MANAGEMENT, PROGRAM, Humans, COHORT, Articles and Commentaries, Ethambutol, media_common, business.industry, multidrug resistant, Extensively drug-resistant tuberculosis, Odds ratio, Pyrazinamide, Middle Aged, medicine.disease, Multiple drug resistance, meta-analysis, Infectious Diseases, Treatment Outcome, tuberculosis, Female, business, FOLLOW-UP, medicine.drug
Abstract

Background. Individualized treatment for multidrug-resistant (MDR) tuberculosis and extensively drug-resistant (XDR) tuberculosis depends upon reliable and valid drug susceptibility testing (DST) for pyrazinamide, ethambutol, and second-line tuberculosis drugs. However, the reliability of these tests is uncertain, due to unresolved methodological issues. We estimated the association of DST results for pyrazinamide, ethambutol, and second-line drugs with treatment outcomes in patients with MDR tuberculosis and XDR tuberculosis.Methods. We conducted an analysis of individual patient data assembled from 31 previously published cohort studies of patients with MDR and XDR tuberculosis. We used data on patients' clinical characteristics including DST results, treatment received, outcomes, and laboratory methods in each center.Results. DST methods and treatment regimens used in different centers varied considerably. Among 8955 analyzed patients, in vitro susceptibility to individual drugs was consistently and significantly associated with higher odds of treatment success (compared with resistance to the drug), if that drug was used in the treatment regimen. Various adjusted and sensitivity analyses suggest that this was not explained by confounding. The adjusted odds of treatment success for ethambutol, pyrazinamide, and the group 4 drugs ranged from 1.7 to 2.3, whereas for second-line injectables and fluoroquinolones, odds ranged from 2.4 to 4.6.Conclusions. DST for ethambutol, pyrazinamide, and second-line tuberculosis drugs appears to provide clinically useful information to guide selection of treatment regimens for MDR and XDR tuberculosis.

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results